Study of KarXT for Alzheimer's Agitation
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Alzheimer's disease from a doctor, with a test like a PET scan or spinal fluid check.
- You must have significant agitation (like restlessness or aggression) that has been present for at least 2 weeks and is not caused by another condition.
- Your memory and thinking test score (MMSE) must be 24 or lower at the start of the study.
- You need a caregiver who can be with you about 8 hours a week, come to all visits, and help with the study.
- You cannot have a history of bipolar disorder, schizophrenia, or certain other mental health conditions.
- You must not be taking certain mood medications, or you must be stable on antidepressants for at least 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.